ライフサイエンスコーパス: beta-2 adrenoceptor

1 to exhibit a high degree of selectivity for beta 2-adrenoceptors.

2 antly via activation of the subpopulation of beta 2-adrenoceptors.

3 rmation of such shape-shifting system as the beta(2)-adrenoceptor.

4 P 20712A, indicating that fenoterol acts via beta(2)-adrenoceptors.

5 Regional infusions of beta(2)-adrenoceptor (ADRB2) agonist have generally show

6 Dietary sodium affects function of the beta-2 adrenoceptor (ADRB2).

7 h Combivent, a combination of a short-acting beta(2)-adrenoceptor agonist (salbutamol) and a short-ac

8 n this study, we examined the effects of the beta(2)-adrenoceptor agonist, fenoterol, on the expressi

9 ition, application of albuterol, a selective beta(2)-adrenoceptor agonist, significantly blocked caps

10 In the treatment of COPD, long-acting beta(2)-adrenoceptor agonists (LABAs) given twice daily

11 studies have demonstrated that although most beta(2)-adrenoceptor agonists activate both G(s) and G(i

12 on of topical long-acting dual D(2)-receptor/beta(2)-adrenoceptor agonists for the treatment of chron

13 xyquinolinone 2-aminoindan derived series of beta(2)-adrenoceptor agonists have been prepared and eva

14 capsaicin selectively activates nociceptors, beta(2)-adrenoceptor agonists may have clinical utility

15 vidence that long-acting agents, such as the beta(2)-adrenoceptor agonists salmeterol and formeterol,

16 s relative to a series of clinical reference beta(2)-adrenoceptor agonists.

17 s alpha coupled much more efficiently to the beta 2 adrenoceptor and the D1 dopamine receptor as dete

18 and examined its ability to couple with the beta(2) adrenoceptor and to activate adenylyl cyclase.

19 otein kinase A phosphorylation status of the beta(2) adrenoceptor and, thereby, its ability to switch

20 wo different G(s)-coupled receptor pathways, beta(2)-adrenoceptors and prostanoid receptors that are

21 nephrine effect was blocked by the selective beta(2)-adrenoceptor antagonist, ICI 118,551, but not by

22 negative inotropic effects of the selective beta(2)-adrenoceptor (AR) antagonist ICI 118,551 in myoc

23 The C terminus of the beta(2)-adrenoceptor (AR) interacts with G protein-coupl

24 ch represents approximately 25% of the total beta(2)-adrenoceptor (AR) population as determined with

25 lioma cell line, which expresses beta 1- and beta 2-adrenoceptors at a ratio of 80:20, was used to in

26 osttranslational modifications (PTMs) of the beta-2 adrenoceptor (B2AR) play a fundamental role in re

27 nase A (PKA)-mediated phosphorylation of the beta(2)-adrenoceptor, because the R,R isomers also marke

28 Beta(2)-adrenoceptor (beta(2)-AR) agonists are very effe

29 Chronic regular use of beta(2)-adrenoceptor (beta(2)-AR) agonists in asthma is

30 MA, linked by a C9 polymethylene chain to a beta(2)-adrenoceptor (beta(2)AR) agonist moiety, represe

31 The beta(2)-adrenoceptor (beta(2)AR) couples to the G-protei

32 examine the architecture of agonist-occupied beta(2)-adrenoceptor (beta(2)AR) in complex with the het

33 Endothelial beta(2)-adrenoceptor (beta(2)AR) stimulation increases n

34 The beta(2)-adrenoceptor (beta(2)AR) was one of the first Fa

35 carinic acetylcholine receptors (mAChRs) and beta-2-adrenoceptors (beta2ARs) are important regulators

36 improvements in inhaled corticosteroids and beta(2)-adrenoceptor bronchodilators.

37 terol exhibits sustained agonist activity at beta 2-adrenoceptors, but not beta 1-adrenoceptors, expr

38 ptor polymorphism is associated with altered beta 2-adrenoceptor expression in asthma patients.

39 Polymorphisms in the gene encoding the beta(2)-adrenoceptor have been associated with interindi

40 eptors and of salmeterol at both beta 1- and beta 2-adrenoceptors in an attempt to determine whether

41 Salmeterol was found to persist at beta 2-adrenoceptors in C6 cells despite washing cell mo

42 these studies demonstrate that activation of beta(2)-adrenoceptors in dental pulp significantly reduc

43 ies have suggested that polymorphisms of the beta 2-adrenoceptor may influence the desensitisation in

44 mpared the temporal characteristics of these beta(2) adrenoceptor-mediated cAMP and CRE-gene transcri

45 any beta antagonists do stimulate very small beta(2) adrenoceptor-mediated cAMP responses, but these

46 ration of action of salmeterol was unique to beta 2-adrenoceptors or, as with formoterol, resulted fr

47 y inhibited GTP gamma S/GppNHp-, AlF(4)(-)-, beta(2)-adrenoceptor plus GTP-, cholera toxin plus GTP-,

48 We have found preliminary evidence that beta 2-adrenoceptor polymorphism is associated with alte

49 termination of their activities at the human beta(2)-adrenoceptor receptor showed symmetrical substit

50 Exchange of Asn-312 and Leu-311 in the beta 2 adrenoceptor resulted in nonfunctional proteins,

51 ore, the sustained activity of salmeterol at beta 2-adrenoceptors seems to be unique and does not res

52 G(i) proteins, fenoterol, a full agonist of beta(2)-adrenoceptor, selectively activates G(s) protein